When these medicinal products are administered to or withdrawn from patients receiving nateglinide, the patient should be observed closely for changes in glycaemic control.
Hvis behandling med disse lægemidler påbegyndes eller standses hos patienter i behandling med nateglinid, skal patienten observeres grundigt for ændringer i den glykæmiske kontrol.